In Wednesday’s Wall Street session, Novo Nordisk ADR (NYSE:NVO) shares traded at $69.82, unchanged from the previous session.
NVO stock price is now 0.76% away from the 50-day moving average and -21.44% away from the 200-day moving average. The market capitalization of the company currently stands at $235.02B.
With the price target maintained at $64, BMO Capital Markets recently Downgraded its rating from Outperform to Market Perform for Novo Nordisk ADR (NYSE: NVO). , while ‘Stifel’ rates the stock as ‘Hold’
In other news, Novo Nordisk A/S, 10% Owner bought 921,897 shares of the company’s stock on May 30 ’25. The stock was bought for $1,972,859 at an average price of $2.14. A total of 0.00% of the company’s stock is owned by insiders.
During the past 12 months, Novo Nordisk ADR has had a low of $57.00 and a high of $143.69. As of last week, the company has a debt-to-equity ratio of 0.86, a current ratio of 0.74, and a quick ratio of 0.56. According to the stock market information, the enterprise value for the company is $383587287040, which is based on a 20.71 price-to-earnings ratio, a 1.09 price-to-earnings-growth ratio, and a beta of 0.66. The fifty day moving average price for NVO is $69.2968 and a two-hundred day moving average price translates $88.86935 for the stock.
The latest earnings results from Novo Nordisk ADR (NYSE: NVO) was released for 2025-03-31. The net profit margin was 34.52% and return on equity was 87.53% for NVO. The company reported revenue of $11.02 billion for the quarter, compared to $9.51 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 15.8 percent. For the current quarter, analysts expect NVO to generate $76.88B in revenue.
